PATENT CLAIM ANALYSIS

Application Number: 15745845
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "312000"]

Abstract:
The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Claim (Index 13):
A method for enhancing cognition in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of  claim 1  or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 86.0
- Lexical Diversity: 1.34615
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15745850', '13384946', '15579115', '13820648', '14443624']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7246041407433159
- 35 USC 102 Novelty (BERT): 0.4829320369797508
- Combined Prediction Score: 0.7004369303669594
- Mean Citation Score: 196.45726600000003
- Max Citation Score: 224.42912
- Similarity Product: 200.7767730770684

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test